50 related articles for article (PubMed ID: 38576619)
1. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
Ning T; Li D; Deng T; Bai Y; Chen Y; Wang Z; Hu B; Ba Y; Lu W
Cancer; 2024 May; ():. PubMed ID: 38781433
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
Li D; Tang L; Hu J; Cao X; He Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
[TBL] [Abstract][Full Text] [Related]
6. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
7. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
[TBL] [Abstract][Full Text] [Related]
9. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
[TBL] [Abstract][Full Text] [Related]
11. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J; Kato K; Raymond E; Hubner RA; Shu Y; Pan Y; Park SR; Ping L; Jiang Y; Zhang J; Wu X; Yao Y; Shen L; Kojima T; Gotovkin E; Ishihara R; Wyrwicz L; Van Cutsem E; Jimenez-Fonseca P; Lin CY; Wang L; Shi J; Li L; Yoon HH
Lancet Oncol; 2023 May; 24(5):483-495. PubMed ID: 37080222
[TBL] [Abstract][Full Text] [Related]
12. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
[TBL] [Abstract][Full Text] [Related]
13. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
Liu J; Gao D; Li J; Hu G; Liu J; Liu D
Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
[TBL] [Abstract][Full Text] [Related]
14. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R; Alsina M; Cervantes A; Leong T; Lordick F; Nilsson M; van Grieken NCT; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):992-1004. PubMed ID: 35914638
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
